Wellington Management Group LLP Buys 15,226 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Wellington Management Group LLP grew its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 0.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,843,447 shares of the biopharmaceutical company's stock after acquiring an additional 15,226 shares during the quarter. Wellington Management Group LLP owned 5.04% of Xenon Pharmaceuticals worth $151,317,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Blue Trust Inc. grew its stake in shares of Xenon Pharmaceuticals by 174.7% in the 3rd quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company's stock valued at $39,000 after purchasing an additional 641 shares during the period. nVerses Capital LLC acquired a new stake in Xenon Pharmaceuticals in the 3rd quarter valued at $102,000. Mirae Asset Global Investments Co. Ltd. grew its position in Xenon Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company's stock valued at $106,000 after acquiring an additional 487 shares during the period. Quarry LP raised its stake in Xenon Pharmaceuticals by 207.7% during the second quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company's stock worth $156,000 after acquiring an additional 2,700 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in Xenon Pharmaceuticals during the second quarter worth $464,000. Institutional investors and hedge funds own 95.45% of the company's stock.

Insider Buying and Selling at Xenon Pharmaceuticals

In related news, Director Gary Patou sold 4,891 shares of the company's stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $41.08, for a total value of $200,922.28. Following the completion of the sale, the director now owns 23,573 shares in the company, valued at $968,378.84. This represents a 17.18 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 5.52% of the company's stock.

Xenon Pharmaceuticals Trading Down 0.4 %

Shares of XENE traded down $0.17 during trading hours on Tuesday, hitting $41.88. 267,169 shares of the stock traded hands, compared to its average volume of 387,803. The business has a fifty day moving average of $41.86 and a 200-day moving average of $40.36. Xenon Pharmaceuticals Inc. has a 1-year low of $35.53 and a 1-year high of $50.99.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.82) by $0.01. During the same quarter last year, the company earned ($0.73) EPS. As a group, research analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on XENE shares. Raymond James reaffirmed an "outperform" rating and issued a $50.00 target price on shares of Xenon Pharmaceuticals in a report on Thursday, October 10th. William Blair raised shares of Xenon Pharmaceuticals to a "strong-buy" rating in a research note on Friday, August 30th. HC Wainwright reiterated a "buy" rating and issued a $53.00 target price on shares of Xenon Pharmaceuticals in a research note on Wednesday, November 13th. Needham & Company LLC restated a "buy" rating and set a $60.00 price target on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $55.00 price objective on shares of Xenon Pharmaceuticals in a research report on Tuesday, September 3rd. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $56.90.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.